Table 2 in vivo lipid lowering activities
S/N | TG (mg/dL) | TC (mg/dL) | HDLC (mg/dL) | LDLC (mg/dL) | VLDLC (mg/dL) |
|---|---|---|---|---|---|
9a | 148.2 | 179.7 | 23.9 | 126.2 | 29.6 |
9b | 156.3 | 176.2 | 45.2 | 99.8 | 31.3 |
9c | 153.6 | 178.3 | 30.9 | 116.7 | 30.7 |
9d | 153.6 | 153.5 | 100.1 | 22.6 | 30.7 |
9e | 165.6 | 171.2 | 52.6 | 85.5 | 33.1 |
9f | 144.6 | 173.1 | 112.8 | 31.4 | 28.9 |
9 g | 157.7 | 166.6 | 85.6 | 49.4 | 31.6 |
9 h | 157.3 | 179.7 | 55.2 | 93.0 | 31.5 |
9i | 165.9 | 169.8 | 23.8 | 112.8 | 33.2 |
9j | 149.9 | 185.3 | 19.2 | 136.1 | 29.9 |
9 k | 146.4 | 163.8 | 132.4 | 2.1 | 29.3 |
9 l | 159.3 | 159.9 | 45.3 | 82.7 | 31.9 |
9 m | 157.3 | 171.2 | 73.9 | 65.9 | 31.5 |
9n | 152.3 | 179.7 | 65.0 | 84.2 | 30.5 |
9o | 157.7 | 166.6 | 85.6 | 49.4 | 31.6 |
gemfibrozil | 145.2 | 174.6 | 110.1 | 35.5 | 29.1 |
control | 173.2 | 206.3 | 70.7 | 101.0 | 34.6 |